S6 show that both GLP-1RA and SGLT-2 inhibitors were associated with a lower risk (13% and 14%, respectively) as compared with placebo and DPP-4 inhibitors (11% and 12%, respectively), although the difference in risks was significant for SGLT-2 vs DPP-4 inhibitors only
At every step, companies must ensure product quality and regulatory compliance
Purpose-built for physicians GLP-1s tied to lower risk for 10 types of cancer compared with insulin in type 2 diabetes Key takeaways: People with type 2 diabetes using a GLP-1 medication have a lower risk for most obesity-associated cancers than insulin users
10.1016/j.cmet.2011.03.016 74 LamD
Costs of Bariatric Surgery with Tricare Getting approved for weight loss surgery with Tricare doesnt mean you wont have any out-of-pocket costs
benefit was preserved in the prespecified subgroup receiving sodium-glucose cotransporter-2 inhibitors (SGLT2i) at baseline, which supports combined GLP-1RA + SGLT2i use as a supported option pursuing complementary pathways [4], [33]
